

May 20, 2021


U.S. Nuclear Regulatory Commission
Attn: Material Licensing Branch
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

Re: Point Biopharma USA Inc. Radioactive Material License 13-35593-01

Dear Sir or Madam,

Point Biopharma USA Inc. respectfully submits this update to its Radioactive Material License 13-35593-01 for your review, providing notification of the following.

Point Biopharma USA Inc. is currently a subsidiary of Point Biopharma Inc. (POINT). As shown in the attached chart, the licensee, Point Biopharma USA Inc. ("Licensee") is currently owned by Point Biopharma Inc. ("POINT"). POINT is in turn owned by 129 shareholders.



POINT is engaging in a financing transaction that will result in a public company, Point Biopharma Global Inc. ("Global"), owning 100% of POINT. The financing transaction will also result in: (i) the current 129 shareholders of POINT continuing to own a majority of the voting stock of Global; (ii) the current directors of POINT becoming directors of Global and continuing to constitute a majority of the board of directors of Global; and (iii) the current officers of POINT becoming the officers of Global.

No changes will be made to the officers or board of directors of Licensee as a result of the financing transaction.

RECEIVED JUN 04 2021

OFFICE 833.544.2637
FAX 647.243.8490

4850 W 78th St Indianapolis, Indiana, 46268, USA



pointbiopharma.com

We do not believe that the financing transaction constitutes a change in control because of the continuation of the existing controlling shareholders described above. In addition, the financing transaction will not result in any decrease in the control or authority over the license and licensed activities that is exercised by the current officers and directors of POINT. The financing transaction will not result in any change to any of Licensee's operations or procedures, licensed materials, persons using the licensed materials, location or use of licensed materials, or persons responsible for licensee's radiation safety program.

Thank you for consideration of our notification. If you have any questions or need further information regarding this, please contact me at your convenience.

Sincerely,

Bill Demers

Bill Demers
Chief Financial Officer
POINT Biopharma Inc.
+1 (647) 401-2182 (M)
bdemers@pointbiopharma.com

FedEx
Express

7 15
398
2 10:30
B 08 04 2005

Align top of FedEx Express shipping label here

ORIGIN ID: MZZA (317) 417-2860	SHIP DATE: 03 JUN 21
POINT BIOPHARMA 4880 W 78TH ST INDIANAPOLIS, IN 46268 UNITED STATES US	ACTWT: 0.15 LB CAD: 8991874/85F02202
	BILL THIRD PARTY

TO **ATTN: MATERIAL LICENSING BRANCH
U.S. NUCLEAR REGULATORY COMMISSION
2443 WARRENVILLE RD STE 210**

LISLE IL 60532

(000) 000-0000 REF: 30271

REL# 3788346

TRK# 7879 0278 2085 **FRI - 04 JUN 10:30A**
(0201) **PRIORITY OVERNIGHT**

XH DPAA 60532
RECEIVED JUN 04 2005

Part # 150207-486J00000-000000022